...
首页> 外文期刊>Bloomberg business week >Sun Pharma Looks Beyond Generics
【24h】

Sun Pharma Looks Beyond Generics

机译:Sun Pharma看起来超越了泛型

获取原文
获取原文并翻译 | 示例
           

摘要

You'd be hard-pressed to find someone who's lost more during the recent upheaval in the generic drug business than Dilip Shanghvi: He forfeited $17 billion to be precise, plus the title of India's richest man.After a four-year decline that erased 65% from the value of Sun Pharmaceutical Industries Ltd., the drugmaker he founded, Shanghvi is preparing to bounce back. He's doing it by borrowing a page from Big Pharma's playbook: investing in higher-margin patented medicines rather than relying solely on copying drugs.
机译:在普通毒品业务中,难以努力找到在最近的仿制药物业务中失去更多的人,而不是Dilip Shanghvi:他被禁止了170亿美元的精确,加上印度最富有的人的称号。经过四年的下降,从Sun Pharmaceutical Industries Ltd.的价值削弱了65%,他成立的药制品人,Shanghvi正在准备反弹。他正在通过借用大型Pharma的剧本借用页面来做的:投资更高版本的专利药物,而不是仅仅依赖于复制药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号